London, UK, Boston, US & Budapest, Hungary, April 25, 2012 - IDBS, a global provider of innovative data management, analytics and modeling solutions, today announced the addition of new functionality to its ChemBook electronic laboratory notebook (ELN). Extending its partnership with ChemAxon, a leading provider of cheminformatics software for the life sciences industry, IDBS has added the Reactor engine, known as the Parallel Synthesis add-on, to support the workflows of chemists, synthesizing libraries of compounds in a parallel fashion.
ChemAxon’s Reactor is a high performance library enumeration engine which produces synthetically relevant virtual libraries giving users a highly efficient, automated workflow that saves time and improves upon best practices in the lab. Chemists can define a generic reaction, a set of reactant structures and combine the two to enumerate and iteratively tune a set of product compounds and discrete reactions on a high throughput scale. This intelligent processing removes tedious recording and drawing out of chemical reactions multiple times.
“Intelligent and flexible enumeration of chemical reactions for compound library design and combinatorial chemistry is an essential capability within an ELN environment. In choosing our Reactor, IDBS is bringing leading edge performance and usability to ChemBook clients,” said Alex Drijver, CEO of ChemAxon. “We look forward to bringing more functionality and performance as we continue to expand our relationship with IDBS.”
ChemAxon’s Reactor enables users to create virtual compound libraries which can be generated under extensive manual control. Users can draw and edit reactants directly, run and tune reactions to achieve real-world products. This approach is particularly advantageous for enumerating small, focused libraries and the IDBS ChemBook user interface ensures that all IP is captured and stored in-house.
“Our winning formula is to provide researchers with innovative tools that enable them to be more effective within an enterprise-wide, scalable data management framework. We empower them and their organizations to benefit from the value of all their research data,” said Neil Kipling, CEO and Founder of IDBS. “Adding the Parallel Synthesis tool to ChemBook provides chemists with what we believe to be the leading technology in the field and further extends our broad ELN capability.”
ChemBook is part of IDBS’ E-WorkBook Suite, a flexible and configurable science-neutral ELN used across enterprises from basic research through to manufacturing. Released with the new version of ChemBook this month, the Parallel Synthesis add-on is an optional capability for users.
For further press information, please contact:
idbs@metia.com
+44 (0)20 3100 3647
About IDBS
IDBS is a global provider of innovative enterprise data management, analytics and modeling solutions. The company’s uniquely sophisticated platform technologies are used by more than 200 pharmaceutical companies, major healthcare providers, global leaders in academic study, and high tech companies to increase efficiency, reduce costs and improve the productivity of industrial R&D and clinical research. IDBS is clearly differentiated by its unique combination of award-winning enterprise technologies and domain knowledge in R&D.
IDBS’ solutions help scientists, hospitals and R&D businesses produce the world’s newest therapeutics, diagnostics and personalized treatments, high-tech materials and consumer products, faster, cleaner engines and fuels, breakthroughs in productive agriculture, healthy, safer food products, and high tech materials and products.
Founded in 1989 and privately held, IDBS is headquartered in Guildford, UK with a direct sales and support presence worldwide. IDBS is a Profit Track 100 company and the recipient of multiple awards including the Frost and Sullivan ‘Enabling Technology’ Award in R&D data management for 2010 and Queen’s Award for International Trade 2011. Further information can be found at www.idbs.com, or follow us on Twitter @IDBSsoftware.
About ChemAxon
ChemAxon is a leader in providing cheminformatics software development platforms and desktop applications for the biotechnology, pharmaceutical and agrochemical industries. With core capabilities for structure visualization, search and management, property prediction, virtual synthesis, screening and drug design, ChemAxon focuses upon active interaction with users and software portability to create powerful, cost effective cross platform solutions and programming interfaces to power modern cheminformatics and chemical communication. The company is privately owned with European headquarters in Budapest and sales and support offices in Europe, Japan and North America.
